Iovance sees long-term response for Amtagvi in first-line melanoma

Iovance의 Amtagvi가 일차성 흑색종에서 장기 반응을 보였다는 소식은 긍정적이나, 구체적 수치가 제한적이어서 영향은 중간 수준입니다.

AI CATALYST SCORE62 / 100Score computed by Sentinel V12

REFERENCE PRICENot measuredReference entry price at analysis time

ANALYSIS HISTORY

IOVA Analysis History (Last 30 Days)

Diagnosed At	Ticker	AI Score	Tier
2026-10-23 19:12:59	IOVA	62	Mid	View Report →
2026-09-29 18:52:11	IOVA	88	S-Class	View Report →
2026-09-29 12:09:13	IOVA	50	Mid	View Report →

RELATED REPORTS

Diagnosed At	Ticker	AI Score	Tier
2026-10-25 19:00:44	GMAB	60	Mid	View Report →
2026-10-25 18:43:11	SMMT	85	Mid	View Report →
2026-10-25 16:22:07	AZN	82	Mid	View Report →
2026-10-25 12:05:03	MRNA	45	Mid	View Report →
2026-10-25 11:15:41	GMAB	50	Mid	View Report →
2026-10-24 19:59:13	AMGN	62	Mid	View Report →
2026-10-24 18:08:27	ZYME	64	Mid	View Report →
2026-10-24 14:39:24	AMGN	90	Mid	View Report →
2026-10-24 14:16:22	LLY	65	Mid	View Report →
2026-10-24 12:28:05	MRNA	65	Mid	View Report →
2026-10-24 05:57:34	ALLO	30	Row	View Report →
2026-10-24 01:58:48	VRTX	60	Mid	View Report →
2026-10-23 20:03:59	BMY	45	Mid	View Report →
2026-10-23 19:02:09	MRNA	50	Mid	View Report →
2026-10-23 16:30:29	MRNA	60	Mid	View Report →
2026-10-23 16:00:41	MRNA	45	Mid	View Report →
2026-10-23 14:52:37	ALNY	68	Mid	View Report →
2026-10-23 09:05:25	MRNA	25	Row	View Report →
2026-10-23 06:33:51	ZLAB	40	Row	View Report →
2026-10-23 02:12:35	UTHR	42	Row	View Report →
2026-10-23 01:00:24	RAPP	55	Mid	View Report →
2026-10-22 21:53:58	MRNA	50	Mid	View Report →
2026-10-22 19:42:35	MRNA	45	Mid	View Report →
2026-10-22 17:39:22	MRNA	45	Mid	View Report →
2026-10-22 15:17:00	MRNA	55	Mid	View Report →
2026-10-22 13:42:28	LNTH	45	Mid	View Report →
2026-10-22 03:44:42	RCUS	45	Mid	View Report →
2026-10-22 02:29:00	QGEN	35	Row	View Report →
2026-10-21 23:40:16	AZN	75	S-Class	View Report →
2026-10-21 22:28:36	ELVN	30	Row	View Report →